Albireo Has Been Granted Orphan Drug Designation For A4250 From The US FDA For The Treatment Of Progressive Familial Intrahepatic Cholestasis (PFIC) And For Primary Biliary Cirrhosis (PBC)
GOTHENBURG, Sweden, November 8, 2012 /PRNewswire/ --
Albireo AB ( Gothenburg, Sweden; "Albireo"), a biopharmaceutical company specializing in gastroenterology, today announced that A4250 (an inhibitor of the ileal bile acid transporter, IBAT/ASBT) has been granted orphan-drug designation by the U.S Food and Drug Administration ("FDA") for the treatment of
- Progressive Familial Intrahepatic Cholestasis (PFIC)
- Primary Biliary Cirrhosis (PBC)
Orphan-drug designation is granted by the FDA to novel drugs that seek to treat a rare disease or condition and provides seven years of market exclusivity for the product upon regulatory approval. Albireo has previously received similar orphan drug designation for the same disease areas from the European Commission.
Orphan designation was granted based on an extensive preclinical data package showing that A4250 has a high potency and a minimal systemic exposure. In addition, substantial benefits were shown in an animal model of cholestasis; the predominant feature of PFIC and PBC."We are very pleased with the FDA´s recognition of our technology with A4250 as an orphan medicinal product for the treatment of these liver diseases," said Dr. Hans Graffner, Chief Medical officer at Albireo. "This designation is an important milestone in our efforts to provide a treatment for patients with cholestatic liver diseases; a disease entity often leading to severe symptoms, liver transplantation and with reduced survival. A4250 is an inhibitor of the bile acid transport mechanism and will decrease the toxic levels of bile acids in the liver cells. The approvals of the orphan drug designation for A4250 both in Europe and in the US provide evidence of the quality of the A4250 research and give us confidence to move forward with the development of A4250 in these liver diseases." About A4250 A4250 belongs to a class of inhibitors of the ileal bile acid transporter (IBAT, syn. apical sodium-dependent bile acid transporter ASBT). A4250 decreases the re-absorption of bile acids and will reduce the toxic levels of bile acids in the liver cells of patients with PFIC and PBC. In preclinical models of cholestasis, treatment with A4250 has been shown to be a very potent inhibitor of IBAT/ASBT with only minimal systemic exposure; thereby reducing the risk for systemic side effects and studies have shown that A4250 decreases the damage in the liver cells and the development of fibrosis/cirrhosis of the liver known to occur in PFIC and PBC. Plans are to move A4250 into clinical studies in 2013. About Progressive Familial Intrahepatic Cholestasis (PFIC) PFIC is a rare disease (approximately 5-10,000 patients in the United States) caused by a genetic defect impairing the transport of bile acids thereby inducing toxic levels of bile acid products in the liver inducing severe symptoms such as intractable itching and scarring of the liver (cirrhosis) early in life. Although milder forms exist, most patients will develop severe symptoms in early childhood. Because medical therapy is ineffective, patients require surgical treatment; otherwise, the disease progresses to liver cirrhosis and failure in the first decade of life. Surgical therapy consists of diversion the bile to a stoma bag or into the large bowel. If the patient does not get better, or if there is evidence of liver cancer, then liver transplantation may be needed.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
24/7 market commentary from Jim Cramer and 20+ veteran Wall Street gurus. Get access to the latest trading ideas on stocks, options, and ETFs as well as a real-time forum to see the pros exchanging their investment ideas.
- Jim Cramer + 20 Wall Street pros
- Intraday commentary & news
- Real-time trading forum
- Actionable trade ideas
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV